Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1188-1195

  Huang, Xin ^a,b,c   Yang, Min ^a   Jin, Jie ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Key Laboratory of Hematology Diagnose and Treatment   (China)

Author keywords

Glucocorticoid receptor microRNAs; Multiple myeloma; Triptolide

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MICRORNA; TRIPTOLIDE;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DOWN REGULATION; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEXAMETHASONE; DITERPENES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MULTIPLE MYELOMA; PHENANTHRENES;

EID: 84861416979     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.638069     Document Type: Article

References (42)

1. arousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657-1664.
2. Chng WJ, Glebov O, Bergsagel PL, et al. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;20:571-596. (Pubitemid 350215376)
3. Moreaux J, Veyrune JL, De Vos J, et al. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer 2009;9:983.
4. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006;66:6675-6682. (Pubitemid 44085624)
5. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436. (Pubitemid 46630462)
6. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-3464.
7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498. (Pubitemid 41007864)
8. Yasui H, Hideshima T, Richardson PG, et al. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006;132:385-397. (Pubitemid 43381614)
9. Tao XL, Sun Y, Dong Y, et al. A prospective, controlled, doubleblind, cross-over study of Tripterygium wilfodii Hook F in treatment of rheumatoid arthritis. Chin Med J (Engl) 1989;102:327-332. (Pubitemid 19197370)
10. Jiang X. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr Nephrol 1994;8:343-344. (Pubitemid 24162277)
11. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 2007; 130:769-774. (Pubitemid 47332575)
12. Tao X, Schulze-Koops H, Ma L, et al. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998;41:130-138. (Pubitemid 28041931)
13. Eff erthT, Li PC, KonkimallaVS, et al. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13:353-361. (Pubitemid 47126989)
14. Shamon LA, Pezzuto JM, Graves JM, et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 1997;112:113-117. (Pubitemid 27067433)
15. Chen BJ. Triptolide, a novel immunosuppressive and antiinfl ammatory agent purifi ed from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001;42:253-265. (Pubitemid 32725582)
16. Kiviharju TM, Lecane PS, Sellers RG, et al. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002;8:2666-2674. (Pubitemid 34856355)
17. Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003;2:65-72.
18. Yang Y, Liu Z, Tolosa E, et al. Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998;40:139-149. (Pubitemid 28439168)
19. Nagase M, Oto J, Sugiyama S, et al. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003;67:1883-1887. (Pubitemid 39251707)
20. Choi YJ, Kim TG, Kim YH, et al. Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and downregulation of XIAP in U937 cells. Biochem Pharmacol 2003;66:273-280. (Pubitemid 36776400)
21. Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006;108:630-637. (Pubitemid 44061364)
22. Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1and nuclear factor-B activation in gastric cancer cells. Oncogene 2001;20:8009-8018. (Pubitemid 34001562)
23. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004;45:373-376. (Pubitemid 38181443)
24. Yang M, Huang J, Pan HZ, et al. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/ Akt/NF-B pathways in human multiple myeloma cells. Int J Mol Med 2008;22:489-496.
25. Lou YJ, Jin J, Wang YG. Triptolide inhibits transcription factor NF-B and induces apoptosis of multiple myeloma cells. Leuk Res 2005;29:99-105.
26. Yang M, Shen JK, Huang J, et al. Interleukin-6-independent expression of glucocorticoid receptor is upregulated by triptolide in multiple myeloma. Leuk Lymphoma 2009;50:802-808.
27. Moalli PA, Pillay S, Weiner D, et al. A mechanism of resistance to glucocorticoid in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992;79:213-222.
28. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006;63:60-72. (Pubitemid 43100281)
29. Smith LK, Shah RR, Cidlowski JA. Glucocorticoids modulate microRNA expression and processing during lymphocyte apoptosis. J Biol Chem 2010;285:36698-36708.
30. ah RG, Kandan-Kulangara F. Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1. Cell Death Diff er 2009;16:858-868.
31. Kumar S, Lacy MQ, Dispenzieril A, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004;34:485-490. (Pubitemid 39264037)
32. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498. (Pubitemid 41007864)
33. Titov DV, Gilman B, He QL. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011;7:182-188.
34. Lee Y, Kim M, Han J. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-4060. (Pubitemid 39472426)
35. Gomi M, Moriwaki K, Katagiri S, et al. Glucocorticoid Effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res 1990;50:1873-1878. (Pubitemid 20098837)
36. Erno V, Carla SLV, Rob M, et al. MicroRNA 18 and 124a downregulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 2009;150:2220-2228.
37. Chang WT, Kang JJ, Lee KY, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001;276:2221-2227. (Pubitemid 32109705)
38. Choi YJ, Kim TG, Kim YH, et al. Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochem Pharmacol 2003;66:273-280. (Pubitemid 36776400)
39. Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006;108:630-637. (Pubitemid 44061364)
40. Carter BZ, Mak DH, Schober WD, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53- mediated increase of DR5. Blood 2008;111:3742-3750.
41. Frese S, Pirnia F, Miescher D, et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003;22:5427-5435. (Pubitemid 37072197)
42. Lee KY, Park JS, Jee YK, et al. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 2002;34:462-468. (Pubitemid 36114364)